View Clinical Trial (Medical Research Study)
Bronchoscopy in Patients With Pulmonary Diseases and Research Volunteers
| City: |
|
Bethesda |
| State: |
|
Maryland |
| Zip Code: |
|
20892 |
| Conditions: |
|
Asthma - Pulmonary Fibrosis |
| Purpose: |
|
Bronchoalveolar lavage (BAL) is a diagnostic and therapeutic procedure conducted by placing
a small fiberoptic scope into the lung of a patient, and injecting sterile water (saline)
into the lung and removing the fluid. The sterile solution removed contains secretions,
cells, and protein from the lower respiratory tract. This sample can be analyzed to provide
more information about possible disease processes going on in the lungs.
This protocol will be used to perform BAL, bronchial brushing, and bronchial wall biopsy in
normal volunteers and patients with pulmonary disease. The samples collected during the
study will be used to examine biochemical processes in the lung that may contribute to lung
disease
|
| Study Summary: |
|
This protocol proposes to perform bronchoalveolar lavage, bronchial brushing and bronchial
wall biopsy in research volunteers and in patients with pulmonary disease to evaluate the
cellular components of normal and diseased lungs. This research study will help to improve
our understanding of pathogenic mechanisms in the lung during progression of pulmonary
disease.
|
| Criteria: |
|
- INCLUSION CRITERIA:
Patients and research volunteers will be accepted for bronchoscopy and bronchoalveolar
lavage only if their heath status will not be compromised by the procedure. Examples of
disease that may be studied under this protocol include alpha-1 antitrypsin deficiency;
lymphangioleiomyomatosis and the cystic lung disease; pulmonary fibrosis; and sarcoidosis.
EXCLUSION CRITERIA:
Patients or research volunteers with abnormalities that contraindicate, or increase the
risk of, fiberoptic bronchoscopy and bronchoalveolar lavage, including a history of
allergy to atropine, lidocaine, or other topical anesthetics or premedications; FEV(1)
less than 0.8 liters; PaO(2), on supplemental 02, of less than 70 mmHg or PaCO(2) greater
than 45 mmHg; presence of uncorrected clotting disorder, uncontrolled hypertension,
significant cardiac disease, renal or liver failure; metastatic disease; hematologic
disorders such as severe anemia (hemoglobin less than or equal to 7 g/ml),
granulocytopenia, or platelet disorders.
Patients or research volunteers with a positive serum test for human immunodeficiency
virus or hepatitis B or C. The rationale for excluding participation on the basis of HIV
seropositivity is because of the known effects of HIV on the lungs.
Patients or research volunteers who are pregnant or lactating.
Patients or research volunteers incapable of giving informed consent.
|
| NCT ID: |
|
NCT00001618 |
| Primary Contact: |
|
Principal Investigator
Joel Moss, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Mary Haughey, R.N.
Phone: (301) 496-3632
Email: mhaughey@nhlbi.nih.gov
|
| Backup Contact: |
|
Email: mossj@nhlbi.nih.gov
Joel Moss, M.D.
Phone: (301) 496-3632
|
| Location Contact: |
|
Bethesda, Maryland 20892
United States
For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)
Phone: 800-411-1222
Email: prpl@mail.cc.nih.gov
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|